Pediatric patients with Prader-Willi syndrome (PWS) can be treated with recombinant human GH (rhGH). These patients are highly sensitive to rhGH and the standard doses suggested by the international guidelines often result in IGF-1 above the normal range. We aimed to evaluate 1 the proper rhGH dose to optimize auxological outcomes and to avoid potential overtreatment, and 2 which patients are more sensitive to rhGH. In this multicenter real-life study, we recruited 215 patients with PWS older than 1 year, on rhGH at least for 6 months, from Italian Centers for PWS care. We collected auxological parameters, rhGH dose, IGF-1 at recruitment and (when available) at start of treatment. The rhGH dose was 4.3 (0.7/8.4) mg/m2/week. At recruitment, IGF-1 was normal in 72.1% and elevated in 27.9% of the patients. In the group of 115 patients with IGF-1 available at start of rhGH, normal pretreatment IGF-1 and uniparental disomy were associated with elevated IGF-1 during the therapy. No difference in height and growth velocity was found between patients treated with the highest and the lowest range dose. The rhGH dose prescribed in Italy seems lower than the recommended one. Normal pretreatment IGF-1 and uniparental disomy are risk factors for elevated IGF-1. The latter seems to be associated with higher sensitivity to GH. In case of these risk factors, we recommend a more accurate titration of the dose to avoid overtreatment and its potential side effects.

Uniparental disomy and pretreatment IGF-1 may predict elevated IGF-1 levels in Prader-Willi patients on GH treatment / Palmieri, V. V.; Lonero, A.; Bocchini, S.; Cassano, G.; Convertino, A.; Corica, D.; Crino, A.; Fattorusso, V.; Ferraris, S.; Fintini, D.; Franzese, A.; Grugni, G.; Iughetti, L.; Lia, R.; Macchi, F.; Madeo, S. F.; Matarazzo, P.; Nosetti, L.; Osimani, S.; Pajno, R.; Patti, G.; Pellegrin, M. C.; Perri, A.; Ragusa, L.; Rutigliano, I.; Sacco, M.; Salvatoni, A.; Scarano, E.; Stagi, S.; Tornese, G.; Trifiro, G.; Wasniewska, M.; Fischetto, R.; Giordano, P.; Licenziati, M. R.; Delvecchio, M.. - In: GROWTH HORMONE & IGF RESEARCH. - ISSN 1096-6374. - 48-49:(2019), pp. 9-15. [10.1016/j.ghir.2019.08.003]

Uniparental disomy and pretreatment IGF-1 may predict elevated IGF-1 levels in Prader-Willi patients on GH treatment

Iughetti L.;Madeo S. F.;
2019

Abstract

Pediatric patients with Prader-Willi syndrome (PWS) can be treated with recombinant human GH (rhGH). These patients are highly sensitive to rhGH and the standard doses suggested by the international guidelines often result in IGF-1 above the normal range. We aimed to evaluate 1 the proper rhGH dose to optimize auxological outcomes and to avoid potential overtreatment, and 2 which patients are more sensitive to rhGH. In this multicenter real-life study, we recruited 215 patients with PWS older than 1 year, on rhGH at least for 6 months, from Italian Centers for PWS care. We collected auxological parameters, rhGH dose, IGF-1 at recruitment and (when available) at start of treatment. The rhGH dose was 4.3 (0.7/8.4) mg/m2/week. At recruitment, IGF-1 was normal in 72.1% and elevated in 27.9% of the patients. In the group of 115 patients with IGF-1 available at start of rhGH, normal pretreatment IGF-1 and uniparental disomy were associated with elevated IGF-1 during the therapy. No difference in height and growth velocity was found between patients treated with the highest and the lowest range dose. The rhGH dose prescribed in Italy seems lower than the recommended one. Normal pretreatment IGF-1 and uniparental disomy are risk factors for elevated IGF-1. The latter seems to be associated with higher sensitivity to GH. In case of these risk factors, we recommend a more accurate titration of the dose to avoid overtreatment and its potential side effects.
2019
48-49
9
15
Uniparental disomy and pretreatment IGF-1 may predict elevated IGF-1 levels in Prader-Willi patients on GH treatment / Palmieri, V. V.; Lonero, A.; Bocchini, S.; Cassano, G.; Convertino, A.; Corica, D.; Crino, A.; Fattorusso, V.; Ferraris, S.; Fintini, D.; Franzese, A.; Grugni, G.; Iughetti, L.; Lia, R.; Macchi, F.; Madeo, S. F.; Matarazzo, P.; Nosetti, L.; Osimani, S.; Pajno, R.; Patti, G.; Pellegrin, M. C.; Perri, A.; Ragusa, L.; Rutigliano, I.; Sacco, M.; Salvatoni, A.; Scarano, E.; Stagi, S.; Tornese, G.; Trifiro, G.; Wasniewska, M.; Fischetto, R.; Giordano, P.; Licenziati, M. R.; Delvecchio, M.. - In: GROWTH HORMONE & IGF RESEARCH. - ISSN 1096-6374. - 48-49:(2019), pp. 9-15. [10.1016/j.ghir.2019.08.003]
Palmieri, V. V.; Lonero, A.; Bocchini, S.; Cassano, G.; Convertino, A.; Corica, D.; Crino, A.; Fattorusso, V.; Ferraris, S.; Fintini, D.; Franzese, A....espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1221912
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 4
social impact